Last reviewed · How we verify
NCT02489838
Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma
trial in Liver Neoplasms in 56 participants. Completed in 7 August 2019.
7 August 2019
Quick facts
| Lead sponsor | Alan Katz |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 56 |
| Start date | 3 February 2012 |
| Primary completion | 7 August 2019 |
| Estimated completion | 7 August 2019 |
| Sites | 1 location across United States |
Conditions studied
- Liver Neoplasms — all drugs for Liver Neoplasms →
Sponsor
Alan Katz
Who can join
18 and older, any sex, with Liver Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To Calculate the amount radiation the lung receives in patients receiving Yttrium-90 for Liver Cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02489838
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Neoplasms
Currently open trials in the same condition.
- NCT07377487 — TheraSphere Japan Pre-Market Study · NA · recruiting
- NCT07473687 — Feasibility Study of Non-Contact Imaging-Based Physiological Monitoring in the Operating Room · recruiting
- NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
- NCT07378709 — Exploratory Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma · recruiting
- NCT06261814 — Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors · Phase 2 · recruiting
Other Alan Katz trials
Trials by the same sponsor.
- NCT03778879 — Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B · Phase 1, PHASE2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02489838 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Alan Katz
- Last refreshed: 11 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02489838.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing